Clene Inc.
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
Nasdaq: CLNN
IR Website: https://invest.clene.com/overview/default.aspx
Headquarters: Salt Lake City, Utah
Content provided by Clene Inc. on 10-1-22.
TALK TO MANAGEMENT
The Clene Inc. management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
Neurodegenerative diseases present unique challenges that must be addressed in novel ways. Decades of research in neurology and the neuroscience fields have shown that many neurodegenerative diseases share a common underlying mechanism: a decline in the cell’s ability to produce energy. Clene’s revolutionary nanotherapeutics have unleashed the extraordinary catalytic activity of elemental nanocrystals to improve cellular energy production in the setting of disease-related stress resulting in neuroprotection, neurorepair, and remyelination. In this way, nanotherapeutics may have broad applicability to disease states for which energy depletion or dysfunction are fundamental.
Our nanotherapeutics are produced utilizing a patented electro-crystal-chemistry process that results in highly-faceted, clean-surfaced nanocrystals of pure transition elements. This process is optimized to control three critical characteristics: size, shape (highly faceted crystal structure) and surfaces (contaminant free) to ensure consistently high catalytic activity for enhanced therapeutic benefit.
Our lead asset, CNM-Au8®, is potentially a first-in-class, orally-delivered, aqueous suspension of catalytically active, gold nanocrystals that improve cellular energy production and utilization. We are currently investigating the clinical potential of CNM-Au8® for the treatment of Amyotrophic Lateral Scierosis (“ALS”), Multiple Scierosis (“MS”) and Parkinson’s Disease (“PD”).
Investor Presentation
Recent News
BioWorld Insider Podcast: Looking ahead to 2023: CEOs contemplate the new normal
Dec 5, 2022
Positive results announced from phase 2 trial of oral MS therapeutic
Dec 1, 2022
Use of Nanoparticles to Combat Neurodegenerative Disease
Nov 10, 2022
CNM-Au8 Shows Survival Benefit in HEALEY Trial: New Top-line Results
Oct 4, 2022
HEALEY ALS director says Clene warrants Phase III test despite miss
Oct 3, 2022
CNM-Au8 Slows Disease Progression in ALS in RESCUE-ALS Phase 2 Trial
Oct 1, 2022
Management Overview
Rob Etherington
Chief Executive Officer and President
Rob Etherington is the President and CEO of Clene Inc. Mr. Etherington brings nearly 30 years of sales, marketing and leadership experience in the pharmaceutical industry to Clene. Prior to joining Clen as CEO, Mr. Etherington worked for Actelion Pharmaceuticals, which was the largest biopharmaceutical company based in the EU until Johnson & Johnson Pharmaceuticals acquired the company in 2017. He initially joined Actelion as founding Director of Marketing in 20000, the same year the company went public, and went on to hold various roles of increasing responsibility. Mr. Etherington served as the first U.S. commercial employee, leading U.S. commercial operations and service as Chair of the U.S. commercial Strategic team where he was responsible for five marketed drugs. Prior to Actelion, Mr. Etherington began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a Team Leader position that oversaw the drug Lipitor. As the founding CEO of Clene, Mr. Etherington has raised more than $150M in equity financings, and has driven Clene’s focus on neurodegenerative diseases.
Mark Mortenson
Chief Science Officer
Mark Mortenson is the Co-Founder and Chief Science Officer of Clene. Mr. Mortenson is the co-inventor of the technology platform developed to produce Clean-Surface Nanocrystal (CSN™) therapeutics, as well as the inventor/co-inventor on 30 other U.S. patents and hundreds of corresponding foreign patents.Mr. Mortenson is a former chief patent counsel responsible for approximately 5500 patents and patent applications in the U.S. and 44 foreign countries, and is the former chief operating officer of research, development, and manufacturing for an advanced materials-based company of more than 300 employees. Mr. Mortenson holds a BS in physics and a BS in ceramic engineering from Alfred University, an MS in material science from Pennsylvania State University, and a JD from George Washington University.
Robert Glanzman
Chief Medical Officer
Dr. Glanzman is board certified in neurology, and a Fellow of the American Academy of Neurology. Dr. Glanzman received his doctorate in medicine from Wake Forest University, completed a residency in neurology at the University of Michigan, and completed fellowship training in diagnostic nuclear medicine at Duke University. Robert spent seven years as Assistant Clinical Professor at Michigan State University, where he led a busy clinical practice, taught residents and acted as principal investigator for numerous clinical trials. Dr. Glanzman joined industry in 1999. He spent eight years at Pfizer as Senior Medical Director and Team Leader of the medical affairs team for interferon beta-1a (Rebif). In 2007, he moved to Novartis where he oversaw the successful U.S. Phase 3 development of fingolimod (Gilenya) and the commercial launch of interferon beta-1b (Extavia. In 2009, he was recruited by the Roche Group as Global Development Team Leader for the ocrelizumab (Ocrevus) program. Dr. Glanzman led the global development of ocrelizumab from the end of Phase 2 through the design and initiation of Phase 3 clinical trials. Following this, Dr. Glanzman held positions of increasing responsibilities at Purdue Pharmaceuticals, Nektar Therapeutics and, from December 2015 to June 2019, was Chief Medical Officer of GeNeuro S.A. In addition to his experience in industry, Dr. Glanzmann has co-authored numerous peer-reviewed publications.
Morgan Brown
Chief Financial Officer
Mr. Morgan Brown has more than 29 years of finance and accounting experience with the last twenty-two years servicing biotechnology, pharmaceutical, medical device and clinical research companies. Prior to joining Clene as CFO, Mr. Brown served in a similar capacity at Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company; at Innovus Pharmaceuticals, Inc. (OTCBB: INNV), an emerging pharmaceuticals company; at World Heart Corporation (NASDAQ: WHRT), a medical device company; at Lifetree Clinical Research, a clinical research organization; and, at NPS Pharmaceuticals Inc. (NASDAQ: NPSP), a biotechnology company. Previously he worked for KPMG LLP, an international public accounting firm, in Salt Lake City where he served as a Senior Audit Manager. In his roles prior to Clene, Mr. Brown has participated in and led efforts to successfully evaluate, negotiate, and close transactions including equity and debt financings totaling over $1 billion and out-licensing of commercial stage asset transactions totaling $220 million. Mr. Brown has experience in sale-leaseback arrangements, facilities construction, and M&A activities. Mr. Brown is a licensed certified public accountant in the state of Utah. Mr. Brown earned a Master of Science degree in Business Administration from the University of Utah and a Bachelor of Science degree in Accounting from Utah State University.
Michael Hotchkin
Chief Development Officer
Michael Hotchkin is the Chief Development Officer of Clene. He has over twenty years of experience in pharmaceutical commercialization, planning, strategy development, and medical affairs. Mr. Hotchkin started his career at Parke-Davis pharmaceuticals and was part of the founding team at Actelion U.S. Inc. launching multiple best-in-class products for orphan disorders. Prior to joining Clene Nanomedicine Inc., He led the commercialization efforts for Actelion’s Genetics Business Unit, including clinical development activities, which resulted in the doubling of sales for two different pharmaceutical drugs. During his 12-year tenure at Actelion, he implemented new market planning activities for Actelion globally, directed U.S. strategy development, and led marketing activities for multiple medicines. At Clene, he leads strategy development, preclinical translational medicine, and health regulatory authority filings.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Clene Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
